Fang Xu

机构：University of Virginia Health System, University of Virginia · ORCID：0000-0002-7163-4671

发表论文 134 篇 · 总被引 2648 次 · h-index 32

代表论文

• A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer (2023 · British Journal of Cancer · 被引 40)
• Neutrophil extracellular traps promote growth of lung adenocarcinoma by mediating the stability of m6A‐mediated SLC2A3 mRNA‐induced ferroptosis resistance and CD8(+) T cell inhibition (2025 · Clinical and Translational Medicine · 被引 24)
• Real-time detection of mature table grapes using ESP-YOLO network on embedded platforms (2024 · Biosystems Engineering · 被引 24)
• Overexpression of PRDM16 attenuates acute kidney injury progression: genetic and pharmacological approaches (2024 · MedComm · 被引 8)
• Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study (2024 · EClinicalMedicine · 被引 8)
• Prevalence of Self-Reported Diagnosed Diabetes Among Adults, by County Metropolitan Status and Region, United States, 2019–2022 (2024 · Preventing Chronic Disease · 被引 5)